Investment
Features
FeesSafety
Academy
More
Pluang+

Compare QUALCOMM, Inc. (QCOM) vs ResMed Inc. (RMD) Price & Performance

QUALCOMM, Inc.Trade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

QUALCOMM, Inc. vs ResMed Inc. — how do they compare? QUALCOMM, Inc. trades at $176.07 (market cap $185.94B), while ResMed Inc. trades at $219.5 (market cap $31.89B). The key difference: QUALCOMM, Inc. is far larger — about 5.8× ResMed Inc.'s market cap, and QUALCOMM, Inc. pays the higher dividend (2.11%). Which is the better fit depends on your goals.

QCOMRMD
Market Cap
$185.94B$31.89B
Sector
TechnologyHealth
52-Week High
$251.10$283.28
52-Week Low
$124.07$182.82
Enterprise Value
$192.90B$31.24B
Dividend Yield
2.11%1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

QUALCOMM, Inc.

Qualcomm (QCOM) trades at $176.4, up 4.54% today, with a bullish technical signal from moving averages and oscillators. The company reported revenue of $44.28B in 2025, with a net income margin of 21.01%. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. Analyst consensus is a Buy with a $200.56 price target, while news highlights AI and data center growth amid smartphone market challenges.

The outlook for QCOM is cautiously optimistic, driven by AI and data center expansion, but near-term risks include smartphone demand softness and margin pressures. Investment opportunity lies in diversification beyond handsets, though competition from Nvidia and Intel poses a threat. Earnings growth and execution on AI initiatives are key catalysts for upside.

ResMed Inc.

ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.

The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About QUALCOMM, Inc.

Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.

Read more on QCOM

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD